Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has experienced a decline in revenue and net profit in H1 2025, with revenue down 7.1% year-on-year to 1.79 billion yuan and net profit down 15.2% to 108 million yuan. The second quarter saw a more significant decline, with revenue down 11.7% and net profit down 16.1% [4] - The report anticipates a recovery in the company's profitability, focusing on the health sector, and maintains a reasonable valuation with the current price-to-earnings ratio (PE) at 35.2 for 2025 [4][5] Financial Performance Summary - H1 2025 revenue by segment: - Cosmetics: 1.094 billion yuan (down 7.7%), with a gross margin of 62.0% (up 0.6 percentage points) - Pharmaceuticals: 207 million yuan (down 13.9%), with a gross margin of 51.8% (down 0.3 percentage points) - Raw materials: 179 million yuan (up 4.2%), with a gross margin of 40.9% (up 1.7 percentage points) - Overall gross margin for H1 2025 was 52.4% (up 0.5 percentage points), indicating improved profitability [5][6] Earnings Forecast - The company has revised its profit forecasts for 2025-2027, now expecting net profits of 246 million yuan, 287 million yuan, and 329 million yuan respectively, with corresponding earnings per share (EPS) of 0.24, 0.28, and 0.32 yuan [4][7] Valuation Metrics - The current PE ratios for 2025, 2026, and 2027 are projected at 35.2, 30.2, and 26.4 respectively, indicating a declining trend in valuation multiples [7][10]

Core Viewpoint - The company reported a decline in revenue and net profit for the first half of 2025, with a focus on the performance of its cosmetics and raw materials businesses [1][2]. Financial Performance - In 1H25, the company achieved revenue of 1.789 billion yuan, a decrease of 7.1% year-on-year, and a net profit attributable to shareholders of 108 million yuan, down 15.2% [1]. - For 2Q25, revenue was 913 million yuan, reflecting an 11.7% decline, with a net profit of 57 million yuan, down 16.1% [1]. - The cosmetics segment generated revenue of 1.094 billion yuan in 1H25, a decrease of 7.7%, with a gross margin of 62.0%, up 0.6 percentage points [2]. Business Segment Analysis - The cosmetics business saw significant growth in the Yilian brand, which achieved revenue of 554 million yuan, up 23.8%, while the Aier Doctor brand experienced a decline of 30.0% to 451 million yuan [2]. - The pharmaceutical products segment generated revenue of 207 million yuan, down 13.9%, with a gross margin of 51.8%, down 0.3 percentage points [2]. - The raw materials and derivatives segment reported revenue of 179 million yuan, an increase of 4.2%, with a gross margin of 40.9%, up 1.7 percentage points [2]. Strategic Initiatives - The company is implementing a "5+N" brand strategy in the cosmetics sector, with the Yilian brand benefiting from promotional activities, leading to a 43% increase in core spray product sales [3]. - The Aier Doctor brand is undergoing adjustments, with positive feedback on the newly launched 287 series [3]. - The company is expanding its pharmaceutical business by developing over 200 hospitals and OTC clients, while also innovating in the "Traditional Chinese Medicine +" sector [3]. Investment Outlook - The company aims to build a beauty and health ecosystem, with strong growth in the Yilian brand and contributions from the raw materials business [3]. - The projected net profits for 2025-2027 are 260 million yuan, 297 million yuan, and 339 million yuan, respectively, with corresponding PE ratios of 33.3, 29.1, and 25.6 [3].